Overview

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts Eye and Ear Infirmary
Treatments:
Acetylcysteine
N-monoacetylcystine
Ophthalmic Solutions
Pharmaceutical Solutions